Our friend and fellow member Manic Muses very kindly gave me the heads up about this bit of news and so I thought I would share it with you all.
Marketwatch.com published an article on Tuesday (July 3rd 2012) announcing…
“PITTSBURGH, July 3, 2012 /PRNewswire via COMTEX/ — Mylan Inc. MYL -1.36% today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lithium Carbonate Extended-release Tablets USP, 300 mg.” 1
Going on to state that…
“This product is the generic version of Noven Therapeutic’s Lithobid® Tablets, which are indicated for the treatment of manic episodes of bipolar disorder and as a maintenance treatment for individuals with a diagnosis of bipolar disorder.(1)”1
Since some of our members have bipolar disorder and thus could be on Lithobid® Tablets we thought this was very much worth sharing with you and our appreciation goes to Manic Muses for giving us the heads up.
The full article published by Marketwatch.com can be found here.
Mental Health Writers' Guild 